The first proteolytic resistant D-enantiomer peptide targeting PD-L1, and a cyclic peptide of LAG-3 developed by our group exhibited significant tumor inhibition as candidates for cancer immunotherapy [22, 23]. The gene discussed is CD274; the disease is neoplasm.